Literature DB >> 5646857

Phase I study with toyocamycin (NSC-63701).

W L Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5646857

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

1.  Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.

Authors:  Janelle M Wright; Linda A Dunn; Zygmunt Kazimierczuk; Anita G Burgess; Kenia G Krauer; Peter Upcroft; Jacqueline A Upcroft
Journal:  Parasitol Res       Date:  2010-06-09       Impact factor: 2.289

2.  Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells.

Authors:  Somnath Pandey; Rahinatou Djibo; Anaïs Darracq; Gennaro Calendo; Hanghang Zhang; Ryan A Henry; Andrew J Andrews; Stephen B Baylin; Jozef Madzo; Rafael Najmanovich; Jean-Pierre J Issa; Noël J-M Raynal
Journal:  Cancers (Basel)       Date:  2022-07-08       Impact factor: 6.575

3.  Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing.

Authors:  M Ri; E Tashiro; D Oikawa; S Shinjo; M Tokuda; Y Yokouchi; T Narita; A Masaki; A Ito; J Ding; S Kusumoto; T Ishida; H Komatsu; Y Shiotsu; R Ueda; T Iwawaki; M Imoto; S Iida
Journal:  Blood Cancer J       Date:  2012-07-20       Impact factor: 11.037

4.  IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma.

Authors:  Yu Tanabe; Yoshiyuki Suehara; Shinji Kohsaka; Takuo Hayashi; Keisuke Akaike; Kenta Mukaihara; Taisei Kurihara; Youngji Kim; Taketo Okubo; Midori Ishii; Saiko Kazuno; Kazuo Kaneko; Tsuyoshi Saito
Journal:  Oncotarget       Date:  2018-02-12

Review 5.  Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Authors:  Nikolaos Tsesmetzis; Cynthia B J Paulin; Sean G Rudd; Nikolas Herold
Journal:  Cancers (Basel)       Date:  2018-07-23       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.